These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 30247919

  • 1. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S, Rood JJM, Buil L, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Mol Pharm; 2018 Nov 05; 15(11):5124-5134. PubMed ID: 30247919
    [Abstract] [Full Text] [Related]

  • 2. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Cancer; 2020 Mar 15; 146(6):1631-1642. PubMed ID: 31304590
    [Abstract] [Full Text] [Related]

  • 3. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2018 Nov 15; 137():47-55. PubMed ID: 30253203
    [Abstract] [Full Text] [Related]

  • 4. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
    Martínez-Chávez A, van Hoppe S, Rosing H, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2019 Sep 03; 16(9):3842-3852. PubMed ID: 31329454
    [Abstract] [Full Text] [Related]

  • 5. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J, Gan C, Retmana IA, Sparidans RW, Li W, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2019 Feb 10; 556():172-180. PubMed ID: 30553002
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2019 Aug 10; 146():104297. PubMed ID: 31175939
    [Abstract] [Full Text] [Related]

  • 8. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.
    Rijmers J, Retmana IA, Bui V, Arguedas D, Lebre MC, Sparidans RW, Beijnen JH, Schinkel AH.
    Biomed Pharmacother; 2024 Jun 10; 175():116720. PubMed ID: 38733773
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites.
    Martínez-Chávez A, Loos NHC, Lebre MC, Tibben MM, Rosing H, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2022 Apr 10; 178():105954. PubMed ID: 34700018
    [Abstract] [Full Text] [Related]

  • 14. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
    Wang Y, Sparidans RW, Potters S, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2021 Oct 10; 172():105850. PubMed ID: 34450308
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.
    Loos NHC, Retmana IA, Rijmers J, Wang Y, Gan C, Lebre MC, Sparidans RW, Beijnen JH, Schinkel AH.
    Biomed Pharmacother; 2023 Oct 10; 166():115304. PubMed ID: 37586117
    [Abstract] [Full Text] [Related]

  • 17. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 Jan 05; 573():118842. PubMed ID: 31759109
    [Abstract] [Full Text] [Related]

  • 18. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
    Li W, Lehutová D, Sparidans RW, Heydari P, Wang J, Lebre MC, Beijnen JH, Schinkel AH.
    Eur J Pharm Biopharm; 2022 Aug 05; 177():135-146. PubMed ID: 35772614
    [Abstract] [Full Text] [Related]

  • 19. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A, Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jul 05; 32(7):2205-16. PubMed ID: 25563977
    [Abstract] [Full Text] [Related]

  • 20. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A, van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Mol Pharm; 2017 Oct 02; 14(10):3258-3268. PubMed ID: 28880088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.